Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006.
Lima, Viviane D. ; Lepik, Katherine J. ; Zhang, Wendy 等
Population-level declines in HIV-related mortality have been
observed in Canada and other resource-rich countries as a result of
effective combination antiretroviral therapy. (1-6) Similar declines
have been observed in resource-limited settings as a result of increased
access to antiretroviral therapy in recent years. (7,8)
Earlier Canadian studies examined localized differences in
HIV-related mortality between provinces and large urban centres. (9-11)
However, little is known about how HIV-related mortality has changed
within different regions in a given province. Understanding these
regional trends is necessary to guide health service planning for the
HIV epidemic. The objective of this study was to characterize changes in
HIV-related mortality in British Columbia (BC) between 1987 and 2006 in
each of the five provincial health authorities and in two urban local
health areas heavily affected by the HIV epidemic.
METHODS
Study design and data sources
We conducted a descriptive, population-based study of HIV-related
mortality trends. The BC Vital Statistics Agency provided death
certificate data for individuals who died from an HIV-related cause
(International Classification of Diseases 10th revision codes B20 to
B24) between 1987 and 2006. Individuals were included in the study if
they had died in BC and were [greater than or equal to] 18 years of age
at the time of death. The death records included date and causes of
death, age, sex and geographical locators for residence at time of
death. Population estimates for BC, broken down by region, age and sex,
were obtained from BC Population Estimates (P.E.O.P.L.E. 32) for the
years 1987 through 2006. (12) Ethical approval to conduct this study was
received from the Providence Health Care/University of British Columbia
Research Ethics Board.
British Columbia Regional Health Boundaries
BC is divided into five regional health authorities: Vancouver
Coastal, Vancouver Island, Fraser, Interior, and Northern. These health
authorities are responsible for the management and delivery of health
services in geographically defined subpopulations of the province. (13)
Vancouver Coastal, Vancouver Island, and Fraser are comparatively small,
densely populated health authorities (with few remote communities). The
Interior is geographically large with many urban centres and scattered
rural communities. The Northern health authority is a vast region with
only one major city and numerous rural and remote communities. Each of
these five health authorities is further broken down into several local
health areas. Within Vancouver Coastal, two local health areas have been
severely affected by the HIV epidemic: Vancouver's City Centre and
Downtown Eastside. (14-16)
Analyses
Annual age- and sex-adjusted HIV-related mortality rates per
100,000 population were calculated for each health authority and for the
two local health areas. Average rates were also calculated for the
entire province and entire study period. All rates were calculated using
the SAS population rates macro, version 6 (Manitoba Centre for Health
Policy and Evaluation, Winnipeg, Manitoba, Canada).
Joinpoint regression was used to identify changes in HIV-related
mortality rates over time for each region. Model development began with
the assumption that a single trend in mortality would best describe the
data. "Joinpoints" (years in which there was a statistically
significant change in mortality trend) were added sequentially and
retained in the model if their inclusion significantly improved model
fit (by the permutation test). (17,18) The final model described the
best-fit number of distinct trends in HIV-related mortality, the annual
percent change in mortality within each trend period and the years in
which changes in trend occurred. Joinpoint analyses were carried out
using Joinpoint version 3.3 (National Cancer Institute, Bethesda,
Maryland, United States).
RESULTS
A total of 3,899 HIV-related deaths were reported in BC between
1987 and 2006, with 2,550 (65.4%) in Vancouver Coastal, 458 (11.8%) in
Vancouver Island, 622 (16.0%) in Fraser, 194 (5.0%) in Interior, and 75
(1.9%) in Northern health authorities. Within the Vancouver Coastal
health authority, 1,164 (45.6%) HIV-related deaths were reported in the
City Centre and 561 (24.9%) were reported in the Downtown Eastside
between 1987 and 2006.
Table 1 summarizes the number of HIV-related deaths and HIV-related
mortality rates per 100,000 population per five-year interval for all
BC, for each health authority and for two local health areas. Throughout
the study period, the absolute number of HIV-related deaths and
mortality rate remained highest in the most densely populated health
authorities (Vancouver Coastal, Fraser, and Vancouver Island) and lowest
in the Interior and North. In Vancouver, the City Centre had the
greatest number of HIV-related deaths and highest HIV-related mortality
rate until 1996. After 1996, HIV-related deaths began to decline in City
Centre, but continued to increase in the Downtown Eastside.
Table 2 summarizes the output of the joinpoint regression analyses
showing temporal trends in HIV-related mortality rates for the
provincial total, each health authority, and the two local health areas.
These trends are graphically depicted in Figures 1 and 2. In BC as a
whole (Figure 1, Panel A), HIV-related mortality significantly increased
between 1987 and 1994 (trend one). In 1994, there was a change in trend
with a significant decrease in HIV-related mortality (trend two). The
year 1998 marked the transition to trend three, reflecting a sustained
reduction in HIV-related mortality.
[FIGURE 1 OMITTED]
As shown in Figure 1, the three-phase pattern of HIV-related
mortality observed at the provincial level was mirrored in Vancouver
Coastal (Panel B), Vancouver Island (Panel C), and Interior (Panel E),
although the mortality declines of trend two did not achieve statistical
significance in Vancouver Island and Interior (Table 2). While Fraser
(Panel D) showed only a two-phase pattern in HIV-related mortality,
trend two showed a steady significant decline from 1993 to 2006. In
contrast, the Northern health authority (Panel F) showed a single trend
of significantly increasing HIV-related mortality from 1987 to 2006.
In Vancouver, the City Centre (Table 2; Figure 2, Panel A)
demonstrated the same three-phase HIV-related mortality trend seen in
Vancouver Coastal, with a significant increase until 1994, followed by a
statistically significant decline between 1994 and 1998, then a
sustained reduction to 2006. In contrast, the Downtown Eastside (Table
2; Figure 2, Panel B) showed a two-phase trend, with the significant
increase in HIV-related mortality persisting until 1997, followed by a
gradual but statistically significant decline. Since 1997, HIV-related
mortality has remained higher in the Downtown Eastside than in City
Centre.
[FIGURE 2 OMITTED]
DISCUSSION
In BC, there were marked changes in HIV-related mortality during
the 20-year period between 1987 and 2006. The three distinct trends in
HIV-related death observed at the provincial level mirror the evolving
HIV epidemic and advances in antiretroviral therapy. Prior to 1992,
there were limited therapeutic options for treating HIV, and HIV-related
mortality rose steadily before this time. The introduction of two-drug
antiretroviral regimens in 1992 was followed by a decrease in
HIV-related mortality, which was consolidated with the widespread
availability of combination antiretroviral therapy starting in 1996.
Investigators in other resource-rich countries have described a similar
three-phase pattern in HIV-related mortality over a comparable date
range. (19)
The substantial decline in HIV-related mortality observed at the
provincial level has been largely driven by changes taking place in the
densely populated, southern regions. Through strength of numbers, the
patterns seen in these regions may overshadow trends in local health
areas. We found regional variation in the changes in HIV-related
mortality over time in BC. In particular, the Northern health authority
showed increasing HIV-related mortality rates at a time when HIV deaths
were decreasing in the other health authorities. Vast geographic area,
low population density, coupled with a relative lack of specialized HIV
resources, are some of the factors that may partially explain this
phenomenon. It should be noted that while the highest rate of new HIV
positive tests was in Vancouver Health Service Delivery Area (30.7 per
100,000 population; 193 cases), the next highest was in the Northern
Interior Health Service delivery area (16.0 per 100,000 population; 23
cases), followed by the South Vancouver Island Health Service delivery
area (9.9 per 100,000 population; 36 cases). (20) Localized differences
are also present within health authorities. The Vancouver Coastal health
authority has substantial HIV-focused health care resources in
comparison to other regions and has seen impressive overall declines in
HIV-related mortality. However, the downturn in HIV-related mortality in
the Downtown Eastside, which is known for a high prevalence of
homelessness, poverty and illicit drug use, (16) occurred at a later
date and has been declining at a slower rate in comparison to the
decline in the relatively affluent and adjacent City Centre. This
intra-regional difference suggests that despite the availability of
specialized HIV-related health care resources in Vancouver, there may be
insufficient HIV-related services, such as outreach programs that
administer antiretroviral therapy, additional HIV training of local
practitioners, and increased HIV testing, to meet the needs of the
population in the Downtown Eastside.
Strengths and limitations
This study has several strengths, including the 20-year study
period and the use of age- and sex-adjusted mortality rates to account
for the changing demographic profile of HIV. The use of cause-specific
HIV-related mortality data rather than all-cause mortality was an
unavoidable limitation because BC has no longitudinal registry of
HIV-infected individuals. It was therefore not possible to describe
non-HIV-related causes of death in HIV-infected individuals. The
accuracy of this reporting of HIV-related causes of death could also
vary by region. The sampling strategy relied on cause of death reported
on the death certificate, therefore, our data may be subject to some
degree of underreporting, including cases where HIV infection was
unrecognized at the time of death or an HIV-related cause of death was
not disclosed on the death certificate. Finally, caution must be
exercised when comparing HIV-related mortality rates across regions,
given the substantial differences in HIV prevalence between regions.
CONCLUSION
Substantial declines in HIV-related mortality have occurred over
the last 20 years in the province of BC. Reductions in HIV-related
mortality have occurred in three distinct phases, mirroring advances in
antiretroviral therapy. The inter- and intra-regional variations in HIV
mortality described here may be due to differential access to health
care, even in a health care system where antiretroviral therapy is
provided at no cost to patients.
These findings have important implications for health service
planning. There is a need for more rigorous and ongoing monitoring of
deaths among HIV-infected individuals by region. Further research is
necessary to determine the primary causes and region-specific influences
of HIV-related mortality. A greater effort is needed to ensure that the
benefit of antiretroviral therapy on HIV mortality is equally felt
across BC. Health care programs--such as outreach programs that
administer antiretroviral therapy--additional training of local
practitioners with support from HIV specialists at major centres, and
increased HIV testing targeted to the special needs of each region need
to be evaluated as a possible means to overcome the excess HIV-related
mortality observed in some regions of BC.
Acknowledgements: The authors acknowledge the contribution of Eric
Druyts to the data analysis and development of an earlier version of
this manuscript. The regional health authorities and the BC Ministry of
Health are also thanked for their input on draft versions of the paper.
Conflict of Interest: Robert Hogg has held grant funding from the
National Institutes of Health, the Canadian Institutes of Health
Research, the Michael Smith Foundation for Health Research, and Health
Canada. He has also received funding from GlaxoSmithKline and Merck
Frosst Laboratories for participating in continued medical education
programmes. Julio Montaner has received grants from, served as an ad hoc
advisor to, or spoken at various events sponsored by Abbott, Argos
Therapeutics, Bioject Inc, Boehringer Ingelheim, BMS, Gilead Sciences,
GlaxoSmithKline, Hoffmann-La Roche, Janssen-Ortho, Merck Frosst, Pfizer,
Schering, Serono Inc, TheraTechnologies, Tibotec, Trimeris. He has also
held grant funding from the Canadian Institutes of Health Research and
the National Institutes of Health. Julio Montaner is a recipient of an
Avant-Garde Award from the National Institute of Drug Abuse. Viviane
Lima has held fellowship support from the Canadian Institutes of Health
Research and the Michael Smith Foundation for Health Research. Katherine
Lepik has held fellowship support from the Michael Smith Foundation for
Health Research.
REFERENCES
(1.) Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et
al. Impact of new antiretroviral combination therapies in HIV infected
patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort
Study. EM] 1997;315(7117):1194-99.
(2.) Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV,
Schechter MT, et al. Improved survival among HIV-infected individuals
following initiation of antiretroviral therapy. JAMA
1998;279(23):1874-75.
(3.) Mocroft A, Youle M, Morcinek J, Sabin CA, Gazzard B, Johnson
MA, et al. Survival after diagnosis of AIDS: A prospective observational
study of 2625 patients. EM] 1997;314(7078):409-13.
(4.) ART-CC. Life expectancy of individuals on combination
antiretroviral therapy in high-income countries: A collaborative
analysis of 14 cohort studies (Antiretroviral Therapy Cohort
Collaboration). Lancet 2008;372(9635):293-99.
(5.) CASCADE Collaboration. Survival after introduction of HAART in
people with known duration of HIV-1 infection. Lancet
2000;355(9210):1158-59.
(6.) Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al.
Continued improvement in survival among HIV-infected individuals with
newer forms of highly active antiretroviral therapy. AIDS
2007;21(6):685-92.
(7.) ART-LINC. Mortality of HIV-1-infected patients in the first
year of antiretroviral therapy: Comparison between low-income and
high-income countries. Lancet 2006;367(9513):817-24.
(8.) Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, Orrell
C, et al. Mortality of HIV-infected patients starting antiretroviral
therapy in Sub-Saharan Africa: Comparison with HIV-unrelated mortality.
PLoS Medicine 2009;6(4):e1000066.
(9.) Hogg RS, Schechter MT, Montaner JS, Goldstone I, Craib K,
O'Shaughnessy MV. Impact of HIV infection and AIDS on death rates
in British Columbia and Canada. CMA] 1994;150(5):711-17.
(10.) Hogg RS, Heath KV, Strathdee SA, Montaner JS,
O'Shaughnessy MV, Schechter MT. HIV/AIDS mortality in Canada:
Evidence of gender, regional and local area differentials. AIDS
1996;10(8):889-94.
(11.) Schanzer DL. Trends in HIV/AIDS mortality in Canada,
1987-1998. Can J Public Health 2003;94(2):135-39.
(12.) British Columbia Ministry of Finance and Corporate Relations.
BC STATS Population Estimates and Projections (P.E.O.P.L.E. 32).
Victoria, BC, 2007.
(13.) British Columbia Ministry of Health Services. British
Columbia Health Authorities. Available at:
http://www.health.gov.bc.ca/socsec (Accessed December 15, 2008).
(14.) Druyts E, Rachlis BS, Lima VD, Harvard SS, Zhang W, Brandson
EK, et al. Mortality is influenced by locality in a major HIV/AIDS
epidemic. HIV Medicine 2009;10(5):274-81.
(15.) Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart
ML, Montaner JS, et al. Needle exchange is not enough: Lessons from the
Vancouver injecting drug use study. AIDS 1997;11(8):F59-65.
(16.) Wood E, Kerr T. What do you do when you hit rock bottom?
Responding to drugs in the city of Vancouver. Int J Drug Policy
2006;17:55-60.
(17.) Kim H, Feuer E, Midthune D. Permutation tests for joinpoint
regression with applications to cancer rates. Statistics Med
2000;19(3):335-51.
(18.) National Cancer Institute, Statistical Research and
Applications Branch. Available at: http://srab.cancer.gov/joinpoint/
(Accessed November 25, 2008).
(19.) Ferreros I, Lumbreras B, Hurtado I, Perez-Hoyos S,
Hernandez-Aguado I. The shifting pattern of cause-specific mortality in
a cohort of human immunodeficiency virus-infected and non-infected
injecting drug users. Addiction 2008;103:651-59.
(20.) Rekart M, Ogilvie G, Gilbert M, Knowles L, Spencer D, Taylor
D, et al. STI prevention and control 2007 annual report. Vancouver, BC:
BC Centre for Disease Control, 2007.
Received: July 31, 2009
Accepted: May 20, 2010
Viviane D. Lima, PhD, [1,2] Katherine J. Lepik, MSc, [1,3] Wendy
Zhang, MSc, [1] Katherine A. Muldoon, BSc, [1] Robert S. Hogg, PhD,
[1,4] Julio S.G. Montaner, MD [1,2]
Author Affiliations
[1.] British Columbia Centre for Excellence in HIV/AIDS, Vancouver,
BC
[2.] Faculty of Medicine, University of British Columbia,
Vancouver, BC
[3.] Faculty of Pharmaceutical Sciences, University of British
Columbia, Vancouver, BC
[4.] Faculty of Health Sciences, Simon Fraser University, Burnaby,
BC
Correspondence and reprint requests: Dr. Julio Montaner, Director,
British
Columbia Centre for Excellence in HIV/AIDS, St. Paul's
Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Tel:
604-806-8036, Fax: 604-806-9044, E-mail:
[email protected]
Funding: No external funding was received for this research.
Table 1. Average Annual HIV-related Deaths and Age--Sex-adjusted HIV-
related Mortality Rates per Five-year Interval (by region, 1987-2006)
Region 1987-1991
Mean (standard deviation)
Deaths per Year Rate *
Provincial
British Columbia 148.0 (45.4) 4.7 (1.3)
Health Authority
Vancouver Coastal 106.0 (33.2) 12.8 (3.5)
Vancouver Island 15.0 (4.6) 2.8 (0.8)
Fraser 21.0 (8.7) 2.1 (0.9)
Interior 4.4 (2.3) 0.8 (0.4)
Northern 2.0 (1.5) 0.5 (0.5)
Local Health Area
City Centre 62.2 (21.4) 76.3 (24.9)
Downtown Eastside 5.8 (2.5) 11.3 (3.5)
Region 1992-1996
Mean (standard deviation)
Deaths per Year Rate *
Provincial
British Columbia 304.0 (29.5) 8.3 (0.8)
Health Authority
Vancouver Coastal 206.0 (21.8) 21.5 (2.6)
Vancouver Island 37.0 (6.1) 5.8 (1.0)
Fraser 45.0 (7.4) 3.8 (0.5)
Interior 13.2 (2.3) 2.2 (0.4)
Northern 4.0 (2.5) 1.2 (0.8)
Local Health Area
City Centre 105.6 (19.8) 106.9 (22.7)
Downtown Eastside 26.6 (11.0) 42.1 (14.3)
Region 1997-2001
Mean (standard deviation)
Deaths per Year Rate *
Provincial
British Columbia 169.0 (5.4) 4.1 (0.1)
Health Authority
Vancouver Coastal 108.0 (5.4) 10.2 (0.6)
Vancouver Island 21.0 (2.8) 3.1 (0.4)
Fraser 29.0 (3.4) 2.1 (0.2)
Interior 8.8 (2.7) 1.4 (0.4)
Northern 2.0 (1.6) 0.7 (0.5)
Local Health Area
City Centre 33.6 (6.1) 30.5 (5.9)
Downtown Eastside 45.0 (2.5) 71.3 (4.1)
Region 2002-2006
Mean (standard deviation)
Deaths per Year Rate *
Provincial
British Columbia 158.0 (12.9) 3.6 (0.3)
Health Authority
Vancouver Coastal 90.0 (14.1) 7.9 (1.2)
Vancouver Island 19.0 (3.1) 2.5 (0.4)
Fraser 29.0 (3.2) 1.9 (0.2)
Interior 12.4 (3.4) 1.7 (0.3)
Northern 7.0 (2.1) 2.5 (0.7)
Local Health Area
City Centre 31.4 (5.5) 26.6 (4.2)
Downtown Eastside 34.8 (9.5) 50.2 (14.0)
* Rates are age-and sex-adjusted and presented per 100,000 population.
Table 2. Joinpoint Regression Results of HIV-related Mortality Rates
(by region, 1987-2006)
Region Trend One
Years APC (95% CI)
Provincial
British Columbia 1987-1994 16.3 (11.5, 21.4) *
Health Authority
Vancouver Coastal 1987-1994 15.5 (9.9, 21.3) *
Vancouver Island 1987-1994 19.5 (10.2, 29.6) *
Fraser 1987-1993 17.3 (1.1, 36.0) *
Interior 1987-1993 23.2 (5.4, 43.9) *
Northern 1987-2006 6.7 (3.3, 10.2) *
Local Health Area
City Centre 1987-1994 12.4 (6.5, 18.7) *
Downtown Eastside 1987-1997 26.1 (16.0, 37.0) *
Region Trend Two
Years APC (95% CI)
Provincial
British Columbia 1994-1998 -20.0 (-30.2, -8.4) *
Health Authority
Vancouver Coastal 1994-1998 -20.9 (-32.7, -7.1) *
Vancouver Island 1994-1997 -23.4 (-47.2, 11.2)
Fraser 1993-2006 -7.4 (-9.9, -4.8) *
Interior 1993-1997 -15.5 (-36.7, 12.7)
Northern -- --
Local Health Area
City Centre 1994-1998 -31.2 (-43.8, -15.9) *
Downtown Eastside 1997-2006 -5.4 (-8.7, -2.1) *
Region Trend Three
Years APC (95% CI)
Provincial
British Columbia 1998-2006 -2.1 (-5.5, 1.4)
Health Authority
Vancouver Coastal 1998-2006 -3.7 (-8.0, 0.8)
Vancouver Island 1997-2006 -2.9 (-8.1, 2.5)
Fraser -- --
Interior 1997-2006 4.4 (-1.3, 10.3)
Northern -- --
Local Health Area
City Centre 1998-2006 -1.9 (-8.2, 4.8)
Downtown Eastside -- --
APC = annual percent change in mortality rate; 95% CI = 95% confidence
interval.
* Significantly different from 0 (p < 0.05).